OMIT Platform
Other Food Allergies (e.g., milk, egg, tree nuts)
Research/Pre-clinicalActive
Key Facts
Indication
Other Food Allergies (e.g., milk, egg, tree nuts)
Phase
Research/Pre-clinical
Status
Active
Company
About Intrommune Therapeutics
Intrommune Therapeutics is a clinical-stage biotech developing a disruptive drug delivery platform for food allergy immunotherapy. Its lead program, INT301, encapsulates allergenic proteins in a toothpaste, enabling daily treatment through routine brushing to desensitize patients via the oral mucosa. The company is targeting a large and growing unmet medical need with a treatment designed to improve adherence and quality of life over current burdensome options. Led by a management team with legal, financial, and clinical expertise, Intrommune is advancing its OMIT platform through clinical development.
View full company profile